Clinical study begins for experimental hemophilia drug

Pfizer launched an early-stage trial of PF-05280602, a modified recombinant factor VIIa for prophylactic and acute treatment of hemophilia. The move represents a milestone payment for Catalyst Biosciences, the compound's developer. Pharmaceutical Business Review Online

Source: AABBsmartbrief